Research and Markets: Biogen-Idec's and Facet Biotech's Daclizumab: Can It ... Fort Mills Times Daclizumab is the active agent in Zenapax (Roche), a humanized antibody that blocks the IL-2 receptor. It was first approved in 1997 for transplant rejection prevention. A phase II study in multiple sclerosis (MS) showed evidence of activity and an ... |
